Key points
- Bevacizumab (Avastin) is an antibody that stops new blood vessels from forming; tumours need these vessels to grow [1].
- It is used for colorectal, lung, kidney, cervical and ovarian cancer, the brain tumour glioblastoma, and liver cancer (with atezolizumab) [1].
- It is given as a drip every 2 or 3 weeks; the first infusion takes 90 minutes and later ones are shorter if it is well tolerated [1].
- The most common side effects: nosebleeds, headache, high blood pressure, a runny nose, protein in the urine and dry skin [1].
- Serious but uncommon side effects: a hole in the bowel, severe bleeding, blood clots and slow wound healing; the drug is stopped at least 4 weeks before surgery [1].
- Women should avoid pregnancy during treatment and for 6 months afterwards and should not breastfeed; the drug may reduce ovarian function [1].
What is this drug and how does it work?
For physicians
Bevacizumab (brand name Avastin) is a humanised IgG1 monoclonal antibody from the group of targeted anti-angiogenic drugs (VEGF inhibitors) [1].
Tumours need a blood supply to grow. A protein called vascular endothelial growth factor (VEGF) binds its receptors (Flt-1 and KDR) on endothelial cells and stimulates their proliferation and the formation of new blood vessels. Bevacizumab binds VEGF and prevents it from binding its receptors [1]. In animal models of colorectal cancer, this reduced microvascular growth and the progression of metastases [1].
Bevacizumab is neither chemotherapy nor immunotherapy, but in most indications it is given with chemotherapy or other drugs [1]. Its main adverse effects relate to blood vessels and blood supply: hypertension, bleeding, thrombosis and impaired wound healing [1].
Which cancers is it used for?
The indications in the table below are based on the US FDA label (revised January 2025), and the label requires no particular biomarker test for them [1]. Bevacizumab was not effective as adjuvant treatment of colon cancer after surgery and is not approved for this use [1]. Approvals may differ between countries, and not every patient with these cancers is a candidate for this drug; the final decision rests with the treatment team.
Your doctor may prescribe this drug for:
- Colorectal cancer that has spread [1]
- Non-squamous non-small cell lung cancer [1]
- Glioblastoma that has come back (adults) [1]
- Kidney cancer that has spread [1]
- Cervical cancer that is persistent, has come back or has spread [1]
- Stage III or IV ovarian, fallopian tube or primary peritoneal cancer after initial surgery [1]
- Platinum-resistant ovarian cancer that has come back [1]
- Platinum-sensitive ovarian cancer that has come back [1]
- Hepatocellular carcinoma [1]
- Ovarian cancer — maintenance with olaparib (not listed in the Avastin label) [1]
Whether it suits you depends on the type and stage of your cancer and your test results. Details of each use are in the section for doctors.
For physicians
| Cancer | Conditions of use |
|---|---|
| Metastatic colorectal cancer | First or second line with intravenous fluorouracil-based chemotherapy; also second line with irinotecan- or oxaliplatin-based regimens after progression on a first-line regimen containing bevacizumab [1] |
| Non-squamous non-small cell lung cancer | First line with carboplatin and paclitaxel in unresectable, locally advanced, recurrent or metastatic disease [1] |
| Recurrent glioblastoma (adults) | Monotherapy [1] |
| Metastatic renal cell carcinoma | With interferon alfa [1] |
| Persistent, recurrent or metastatic cervical cancer | With paclitaxel and cisplatin or paclitaxel and topotecan [1] |
| Stage III or IV ovarian, fallopian tube or primary peritoneal cancer after initial surgery | With carboplatin and paclitaxel, followed by single-agent maintenance [1] |
| Platinum-resistant recurrent ovarian cancer | With paclitaxel, pegylated liposomal doxorubicin or topotecan in patients with no more than 2 prior chemotherapy regimens [1] |
| Platinum-sensitive recurrent ovarian cancer | With carboplatin and paclitaxel or carboplatin and gemcitabine, followed by monotherapy [1] |
| Hepatocellular carcinoma | With atezolizumab in unresectable or metastatic disease without prior systemic therapy [1] |
| Ovarian cancer — maintenance with olaparib (not listed in the Avastin label) | With olaparib after response to first-line chemotherapy; this combination is not among the Avastin label indications [1] |
| Cancer | Key evidence |
|---|---|
| Metastatic colorectal cancer | AVF2107g trial: median overall survival 20.3 vs 15.6 months (hazard ratio 0.66) with IFL; E3200 and ML18147 trials in second line [1, 2] |
| Non-squamous non-small cell lung cancer | E4599 trial: median overall survival 12.3 vs 10.3 months (hazard ratio 0.80) [1, 3] |
| Recurrent glioblastoma (adults) | EORTC 26101 trial: no difference in overall survival (hazard ratio 0.91); median progression-free survival 4.2 vs 1.5 months with lomustine [1, 4] |
| Metastatic renal cell carcinoma | BO17705 trial: median progression-free survival 10.2 vs 5.4 months (hazard ratio 0.60); no improvement in overall survival [1, 5] |
| Persistent, recurrent or metastatic cervical cancer | GOG-0240 trial: median overall survival 16.8 vs 12.9 months (hazard ratio 0.74) [1, 6] |
| Stage III or IV ovarian, fallopian tube or primary peritoneal cancer after initial surgery | GOG-0218 trial: median progression-free survival 18.2 vs 12.0 months (hazard ratio 0.62), with no significant difference in overall survival [1, 7]; ICON7 trial at 7.5 mg/kg [8] |
| Platinum-resistant recurrent ovarian cancer | MO22224 (AURELIA) trial: median progression-free survival 6.8 vs 3.4 months (hazard ratio 0.38) [1, 9] |
| Platinum-sensitive recurrent ovarian cancer | AVF4095g trial: median progression-free survival 12.4 vs 8.4 months; GOG-0213 trial: median overall survival 42.6 vs 37.3 months [1] |
| Hepatocellular carcinoma | IMbrave150 trial: hazard ratio for death 0.58 compared with sorafenib [1, 10] |
| Ovarian cancer — maintenance with olaparib (not listed in the Avastin label) | PAOLA-1 trial: median progression-free survival 22.1 vs 16.6 months, and 37.2 vs 17.7 months in HRD-positive patients [11] |
How it is taken and dosing
Show detailsHide
Treatment regimens and doses: index9 regimens
Bevacizumab is given at a treatment centre as an intravenous infusion. The first infusion takes 90 minutes; if it is well tolerated, the second is given over 60 minutes and, if that is tolerated, later ones over 30 minutes [1]. Depending on the cancer, it is given every 2 or 3 weeks, usually with chemotherapy or another drug [1].
How long treatment lasts depends on the cancer; for example, in ovarian cancer after initial surgery it is given for up to 22 cycles, and in many other cases until the disease progresses [1].
Monitoring during treatment: blood pressure is measured every 2 to 3 weeks, and a urine test for protein is repeated regularly [1]. In hepatocellular carcinoma, a check for varices within 6 months of starting treatment is recommended [1].
Surgery: if you have surgery coming up, be sure to tell your treatment team; bevacizumab must be stopped at least 28 days before planned surgery and not restarted until at least 28 days after major surgery and until the wound has fully healed [1].
- Administration: diluted in a total of 100 mL of 0.9% sodium chloride (do not mix or give with dextrose); first infusion 90 minutes, second 60 minutes and, if tolerated, later ones 30 minutes [1].
- Surgery: stop at least 28 days before elective surgery and do not start until at least 28 days after major surgery and adequate wound healing [1].
- Monitoring: blood pressure every 2 to 3 weeks (and after stopping in patients who developed hypertension); urine protein by serial dipstick; at 2+ or more, a 24-hour urine collection [1].
- No dose reductions are recommended; the drug is continued, withheld or discontinued [1].
- Discontinue permanently: gastrointestinal perforation, tracheo-oesophageal fistula, grade 4 fistula or any internal organ fistula; necrotising fasciitis; grade 3 to 4 haemorrhage; severe arterial thromboembolism; grade 4 venous thromboembolism; hypertensive crisis or encephalopathy; PRES; nephrotic syndrome; severe infusion reaction; congestive heart failure [1].
- Withhold temporarily: wound-healing complications (until adequate healing); recent haemoptysis ≥2.5 mL; severe uncontrolled hypertension (until controlled); proteinuria ≥2 g/24 h without nephrotic syndrome (until below 2 g) [1].
- Infusion reaction: mild: slow the rate; clinically significant: interrupt and resume at a lower rate once symptoms resolve; severe: discontinue permanently [1].
For physicians
Dosing by cancer: colorectal, lung, brain, kidney and liver (FDA label)
Metastatic colorectal cancer
First or second line with intravenous fluorouracil-based chemotherapy; or second line after progression on a first-line regimen containing bevacizumab
First or second line with intravenous fluorouracil-based chemotherapy; or second line after progression on a first-line regimen containing bevacizumab
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| With bolus IFL | |||
| Bevacizumab | 5 mg/kg | IV | Every 2 weeks |
| With FOLFOX4 | |||
| Bevacizumab | 10 mg/kg | IV | Every 2 weeks |
| Second line after bevacizumab (with a fluoropyrimidine-irinotecan or -oxaliplatin regimen) | |||
| Bevacizumab | 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks | IV | |
Not indicated for adjuvant treatment of colon cancer [1].
Bevacizumab + carboplatin + paclitaxel (E4599)
Advanced, recurrent or metastatic non-squamous NSCLC, first lineCycle length: Every 21 days
Advanced, recurrent or metastatic non-squamous NSCLC, first line
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| 6 cycles | |||
| Bevacizumab | 15 mg/kg | IV | Day 1 |
| Paclitaxel | 200 mg/m² | IV | Day 1 |
| Carboplatin | AUC 6 | IV | Day 1 |
| Maintenance | |||
| Bevacizumab | 15 mg/kg | IV | Every 3 weeks |
Chemotherapy doses are from the E4599 trial in the label. In E4599, predominantly squamous histology, brain metastases, gross haemoptysis (half a teaspoon or more), unstable angina and therapeutic anticoagulation were exclusion criteria [1].
Recurrent glioblastoma
AdultsCycle length: Every 14 days
Adults
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Bevacizumab | 10 mg/kg | IV | Every 2 weeks |
In the EORTC 26101 trial it was given with lomustine 90 mg/m² every 6 weeks [1].
Metastatic renal cell carcinoma
With interferon alfaCycle length: Every 14 days
With interferon alfa
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Bevacizumab | 10 mg/kg | IV | Every 2 weeks |
| Interferon alfa | 9 million units three times a week (up to 52 weeks; BO17705 trial) | Subcutaneous |
Dosing as per the FDA label [1].
Bevacizumab + atezolizumab
Unresectable or metastatic hepatocellular carcinoma without prior systemic therapyCycle length: Every 21 days
Unresectable or metastatic hepatocellular carcinoma without prior systemic therapy
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Atezolizumab | 1200 mg | IV, first | Day 1 |
| Bevacizumab | 15 mg/kg | IV, after atezolizumab | Day 1 |
Assess and treat varices within 6 months before starting, as in the IMbrave150 trial [1].
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Dosing in gynaecological cancers: cervix and ovary (FDA label)
Cervical cancer (GOG-0240)
Persistent, recurrent or metastatic diseaseCycle length: Every 21 days
Persistent, recurrent or metastatic disease
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Bevacizumab | 15 mg/kg | IV | Day 1 |
| Option 1 | |||
| Paclitaxel + cisplatin | Paclitaxel 175 mg/m² (3 hours) + cisplatin 50 mg/m² | IV | Day 1 (or cisplatin on day 2) |
| Option 2 | |||
| Paclitaxel + topotecan | Paclitaxel 175 mg/m² on day 1 + topotecan 0.75 mg/m² (30 minutes) | IV | Topotecan on days 1 to 3 |
Chemotherapy doses are from the GOG-0240 trial in the label (the trial's other option: paclitaxel 135 mg/m² over 24 hours on day 1 and cisplatin on day 2) [1].
Stage III or IV ovarian cancer after initial surgery (GOG-0218)
Epithelial ovarian, fallopian tube or primary peritoneal cancerCycle length: Every 21 days
Epithelial ovarian, fallopian tube or primary peritoneal cancer
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Up to 6 cycles | |||
| Bevacizumab | 15 mg/kg | IV | Day 1 |
| 6 cycles | |||
| Carboplatin + paclitaxel | AUC 6 + 175 mg/m² | IV | Day 1 |
| Maintenance | |||
| Bevacizumab | 15 mg/kg | IV | Every 3 weeks |
In GOG-0218, bevacizumab was started with chemotherapy cycle 2 [1].
Evidence: GOG-0218 (2011)
Platinum-resistant recurrent ovarian cancer (MO22224)
Recurrence less than 6 months after platinum; no more than 2 prior regimensCycle length: Every 2 or 3 weeks
Recurrence less than 6 months after platinum; no more than 2 prior regimens
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Option 1 | |||
| Bevacizumab | 10 mg/kg every 2 weeks | IV | |
| With one of | |||
| Paclitaxel / pegylated liposomal doxorubicin / weekly topotecan | Paclitaxel 80 mg/m² on days 1, 8, 15 and 22 every 4 weeks; PLD 40 mg/m² on day 1 every 4 weeks; topotecan 4 mg/m² on days 1, 8 and 15 every 4 weeks | IV | |
| Option 2 | |||
| Bevacizumab + topotecan | 15 mg/kg every 3 weeks + topotecan 1.25 mg/m² on days 1 to 5 every 3 weeks | IV | |
Chemotherapy doses are from the MO22224 trial in the label [1].
Platinum-sensitive recurrent ovarian cancer
Epithelial ovarian, fallopian tube or primary peritoneal cancerCycle length: Every 21 days
Epithelial ovarian, fallopian tube or primary peritoneal cancer
Before prescribing: Prescribing notes| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Option 1: 6 to 8 cycles (GOG-0213) | |||
| Bevacizumab + carboplatin + paclitaxel | 15 mg/kg + AUC 5 + 175 mg/m² (3 hours) | IV | Day 1 |
| Option 2: 6 to 10 cycles (AVF4095g) | |||
| Bevacizumab + carboplatin + gemcitabine | 15 mg/kg + AUC 4 (day 1) + gemcitabine 1000 mg/m² | IV | Gemcitabine on days 1 and 8 |
| Maintenance | |||
| Bevacizumab | 15 mg/kg | IV | Every 3 weeks |
Dosing as per the FDA label [1].
Before prescribing, check each dose against the drug label, laboratory tests and the patient’s condition.
Side effects
The most common side effects:
For physicians
Based on 4463 patients in clinical trials, the most common adverse reactions to bevacizumab (alone or with other anticancer drugs), with a frequency above 10%, are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, haemorrhage, lacrimation disorder, back pain and exfoliative dermatitis [1].
For example, the frequency of some adverse reactions in two large trials [1]:
- Renal cell carcinoma, with interferon alfa (BO17705 trial): fatigue 33% (vs 27%), hypertension 28% (vs 9%), epistaxis 27% (vs 4%), headache 24% (vs 16%) and proteinuria 20% (vs 3%) [1].
- Ovarian cancer after surgery, with carboplatin and paclitaxel followed by maintenance (GOG-0218 trial): headache 34% (vs 21%), hypertension 32% (vs 14%) and epistaxis 31% (vs 9%) [1].
Mild bleeding, mostly grade 1 epistaxis, is the most common bleeding pattern with this drug [1].
Serious side effects
These are less common but serious; tell your team early if you notice any sign of them:
- A hole in the bowel: sudden severe abdominal pain, fever or vomiting; rare but dangerous, mostly in the first months [1].
- Slow wound healing: if you are going to have surgery, your doctor will stop the drug for some weeks before and after the operation [1].
- Severe bleeding, such as coughing up blood or black stools; tell your doctor if you have recently coughed up blood [1].
- Blood clots, stroke or heart attack: chest pain, weakness on one side of the body, trouble speaking, or pain and swelling in one leg [1].
- Very high blood pressure, or a severe headache, seizures, confusion and blurred vision [1].
- Reduced ovarian function in young women, a weak heart and harm to an unborn baby [1].
For physicians
The current FDA label for Avastin has no boxed warning but lists these important warnings [1]:
- Gastrointestinal perforation and fistula: serious and sometimes fatal perforation occurred in 0.3% to 3% of patients (highest with prior pelvic radiotherapy), mostly within the first 50 days. Serious fistula in less than 1% to 1.8% (highest in cervical cancer) [1]. In ovarian cancer, avoid use with rectosigmoid or bowel involvement or symptoms of bowel obstruction [1].
- Impaired wound healing: 15% vs 4% in colorectal cancer patients who had surgery during treatment; necrotising fasciitis (sometimes fatal) has also been reported [1].
- Haemorrhage: grade 3 to 5 bleeding in 0.4% to 7%; serious or fatal pulmonary haemorrhage in 31% of patients with squamous and 4% with non-squamous lung cancer receiving it with chemotherapy. Do not give it to a patient who has recently coughed up half a teaspoon (2.5 mL) or more of blood [1].
- Arterial thromboembolic events (stroke, transient ischaemic attack, myocardial infarction, angina): grade 3 to 5 in 5% vs 2% or less; the risk is higher with prior arterial thromboembolism, diabetes or age over 65 [1].
- Venous thromboembolic events: grade 3 to 4 in 11% vs 5% in the GOG-0240 trial [1].
- Severe hypertension: grade 3 to 4 in 5% to 18% [1].
- Posterior reversible encephalopathy syndrome (PRES): less than 0.5%; presents with headache, seizures, lethargy, confusion and visual disturbance [1].
- Renal injury and proteinuria: grade 3 to 4 proteinuria in 0.7% to 7%; nephrotic syndrome in less than 1% [1].
- Infusion reactions: with the first dose in less than 3%, severe in 0.4% [1].
- Ovarian failure: 34% vs 2% in premenopausal women; recovery of ovarian function after stopping was seen in 22% [1].
- Congestive heart failure: grade 3 or higher left ventricular dysfunction in 1% vs 0.6%; with prior anthracycline, heart failure in 4% vs 0.6% [1].
- Embryo-fetal toxicity: birth defects were seen in animal studies [1].
When should I call my doctor?
Contact your treatment team straight away if you have any of these symptoms [1]:
- High fever, chills, severe or persistent abdominal pain, severe constipation or vomiting (possible bowel perforation)
- Any serious or unusual bleeding, especially coughing or spitting up blood
- Signs of an arterial or venous clot, such as symptoms of a stroke or heart attack, chest pain or sudden shortness of breath
- A change in blood pressure or a severe headache
- New or worsening nervous system symptoms such as headache, seizures, confusion, sleepiness or vision problems
- Signs of nephrotic syndrome such as unusual swelling of the body
- Signs of heart failure such as shortness of breath or swollen legs
- During or after an infusion: wheezing, chest pain, headache, chills or sweating
- A surgical wound that does not heal or opens up
In severe cases (such as heavy bleeding, chest pain, signs of a stroke or a seizure), call your local emergency number.
Interactions, pregnancy and precautions
Drug interactions: according to the label, bevacizumab had no clinically meaningful effect on the pharmacokinetics of irinotecan (and its active metabolite SN38), interferon alfa, carboplatin or paclitaxel, although in 3 of 8 patients receiving bevacizumab with paclitaxel and carboplatin, paclitaxel exposure was lower after 4 cycles [1]. Bevacizumab is not indicated for use with anthracycline-based chemotherapy [1].
Pregnancy and contraception: bevacizumab may harm an unborn baby. Women who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and tell their doctor if they become pregnant or think they might be [1].
Breastfeeding: do not breastfeed during treatment and for 6 months after the last dose [1].
Fertility: this drug increases the risk of ovarian failure and its long-term effects on fertility are not known; talk to your doctor about egg preservation before starting treatment [1].
Vaccines: the FDA label gives no specific advice about vaccination [1]; talk to your treatment team before any vaccine.
Missed appointment: if you miss an infusion, contact your treatment team as soon as possible to rearrange it.
Older adults: the risk of blood clots in the arteries with bevacizumab is higher in people aged 65 and over; report chest pain, weakness on one side of the body or trouble speaking straight away [1].
Children: safety and effectiveness in children have not been established, and the drug is not approved for people under 18 [1].
Frequently asked questions
Is bevacizumab chemotherapy?
No. Bevacizumab is a targeted antibody that blocks VEGF and so stops the tumour from growing new blood vessels [1]. In most uses, though, it is given with chemotherapy, for example with carboplatin and paclitaxel in lung cancer [1].
Why do they keep checking my blood pressure and urine during treatment?
High blood pressure and protein in the urine are known side effects of this drug. The label recommends measuring blood pressure every 2 to 3 weeks and repeating urine tests regularly, so that blood pressure treatment can be started or the infusions paused if needed [1].
Do I need to stop the drug before surgery?
Yes. Bevacizumab slows wound healing; it must be stopped at least 28 days before planned surgery and not restarted until at least 28 days after major surgery and until the wound has fully healed [1]. Your treating doctor decides when to stop and restart it.
How long does each infusion take?
The first infusion takes 90 minutes, the second 60 minutes if tolerated, and later ones 30 minutes if tolerated [1]. If it is given with chemotherapy or atezolizumab, the whole session will be longer.
Scientific evidence
Show detailsHide
Key studies
7 itemsA phase 3 trial of bevacizumab in ovarian cancer
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Improved survival with bevacizumab in advanced cervical cancer
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Related cancer types
Treatment regimens (physicians)
References
11 referencesShow all references, 10 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1AVASTIN (bevacizumab) injection, for intravenous use: Prescribing InformationSource Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108
- 2Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- 3Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- 4Lomustine and Bevacizumab in Progressive Glioblastoma
- 5Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
- 6Improved survival with bevacizumab in advanced cervical cancer
- 7Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- 8A phase 3 trial of bevacizumab in ovarian cancer
- 9Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- 10Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- 11Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/drugs/bevacizumab/